Metraipolis › archive › dc_e8602f9db384
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis — Europe PMC PMID:42563503
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42563503
- DOI
- 10.1111/1759-7714.70362
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-06T18:59:33.657Z
- SHA-256 of the archived text
7abce6d9a40c6b1bf35b98d071f58f6881ee602ec51ebc0294efd5d2b185c3b0- Stable URL of this page
https://metraipolis.com/documento/dc_e8602f9db384
How to cite
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis — Europe PMC PMID:42563503 — Europe PMC (en), https://europepmc.org/article/MED/42563503 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e8602f9db384 (Metraipolis archive dc_e8602f9db384, sha256 7abce6d9a40c6b1bf35b98d071f58f6881ee602ec51ebc0294efd5d2b185c3b0)
BibTeX
@misc{dce8602f9db384,
title = {Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis — Europe PMC PMID:42563503},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42563503},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e8602f9db384; sha256 7abce6d9a40c6b1bf35b98d071f58f6881ee602ec51ebc0294efd5d2b185c3b0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42563503. Agents can read the archived copy with the MCP tool read_document.